Vaccines (Feb 2024)

High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5

  • Jochen M. Wettengel,
  • Hiroaki Naka,
  • Gregory A. Dissen,
  • Jeffrey Torgerson,
  • Michelle Pounder,
  • Simon F. Mueller,
  • Elisabeth Mueller,
  • Philipp Hagen,
  • Micah Brandt,
  • Ulrike Protzer,
  • Benjamin J. Burwitz

DOI
https://doi.org/10.3390/vaccines12020155
Journal volume & issue
Vol. 12, no. 2
p. 155

Abstract

Read online

Adenoviral vectors based on the human adenovirus species C serotype 5 (HAdV-C5) are commonly used for vector-based gene therapies and vaccines. In the preclinical stages of development, their safety and efficacy are often validated in suitable animal models. However, pre-existing neutralizing antibodies may severely influence study outcomes. Here, we generated a new HAdV-C5-based reporter vector and established a high-throughput screening assay for the multivalent detection of HAdV-C5-neutralizing antibodies in serum. We screened the sera of rhesus macaques at different primate centers, and of rabbits, horses, cats, and dogs, showing that HAdV-C5-neutralizing antibodies can be found in all species, albeit at different frequencies. Our results emphasize the need to prescreen model animals in HAdV-C5-based studies.

Keywords